Business Context and Reporting Period
Company: Aclaris Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 23, 2016
Reporting Period: Fourth Quarter and Full Year ended December 31, 2015
This filing serves as a notification that the company issued a press release announcing its financial results for the specified period. The detailed financial data is contained in the press release furnished as Exhibit 99.1 and is incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K filing.
Material Changes
The filing text does not provide specific details regarding material changes versus prior periods. It only confirms the announcement of results for the quarter and year ended December 31, 2015.
Guidance, Outlook, and Risks
Management Commentary: The company announced a conference call to discuss the financial results.
Legal Disclaimer: In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liability of that section. It is not incorporated by reference into other filings unless expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 23, 2016) for specific revenue, net loss, and cash position figures.
- Verify the details of the conference call mentioned for management commentary and Q&A.
- Confirm the status of the company's pipeline and operational milestones as discussed in the referenced press release.
- Note the legal limitation that the financial data in this specific 8-K is not deemed "filed" under Section 18 of the Exchange Act.